Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies for central nervous system disorders characterized by neuronal excitation-inhibition imbalance. The company offers cerebrum, a small molecule platform for CNS small molecule therapies and solidus, an antisense oligonucleotide platform to discover and develop antisense oligonucleotide. It is developing ulixacaltamide, a small molecule inhibitor of T-type calcium channels that is in Phase III clinical trial for the treatment of essential tremor; vormatrigine, a small molecule targeting the hyperexcitable state of sodium-channels in the brain to treat focal onset epilepsy; relutrigine for the treatment of developmental and epileptic encephalopathies; PRAX-020; and PRAX-050. In addition, the company develops elsunersen, a clinical-stage ASO designed to regulate NaV1.2 expression for the treatment of SCN2A-DEE; PRAX-080; PRAX-090; and PRAX-100. It has a license agreement with RogCon Inc.; and research collaboration and license agreement with Ionis Pharmaceuticals, Inc. The company was incorporated in 2015 and is based in Boston, Massachusetts.

Praxis Precision Medicines, Inc.

In a report released today, Douglas Tsao from H.C. Wainwright reiterated a Buy rating on Praxis Precision Medicines, with a price target of $1,201....

H.C. Wainwright Sticks to Its Buy Rating for Praxis Precision Medicines (PRAX)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Praxis Precision Medicines (PRAX), BioCryst (BCRX) a...

Analysts Offer Insights on Healthcare Companies: Praxis Precision Medicines (PRAX), BioCryst (BCRX) and GH Research (GHRS)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Tenaya Therapeutics (TNYA), Privia Health Group (PRV...

Analysts Offer Insights on Healthcare Companies: Tenaya Therapeutics (TNYA), Privia Health Group (PRVA) and Praxis Precision Medicines (PRAX)

Praxis Precision Medicines, Inc. ($PRAX) announced an update on their ongoing clinical study. Praxis Precision Medicines is running an extension st...

Praxis Extends Vormatrogine Epilepsy Trial, Keeping Long-Term Growth Story in Play

Goldman Sachs analyst Kevin Strang initiated coverage with a Buy rating on Praxis Precision Medicines on July 17 and set a price target of $447.00....

Praxis Precision Medicines (PRAX) Has a New Rating from Goldman Sachs

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Alkermes (ALKS), TransMedics Group (TMDX) and Praxis Precision Me...

Analysts Conflicted on These Healthcare Names: Alkermes (ALKS), TransMedics Group (TMDX) and Praxis Precision Medicines (PRAX)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Praxis Precision Medicines (PRAX), Sino Biopharmaceu...

Analysts Are Bullish on Top Healthcare Stocks: Praxis Precision Medicines (PRAX), Sino Biopharmaceutical (SBMFF)

RBC Capital analyst Leonid Timashev maintained a Buy rating on Praxis Precision Medicines yesterday and set a price target of $449.00. According to...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	PRAX	$360.76	-2.54%	454.89K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	PRAX	$360.76	-2.5%	454.89K
3
4
5
6

PRAX

PRAX

Get Praxis Precision Medicines, Inc. Data in Excel

Get Praxis Precision Medicines, Inc. Data in Excel